Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Job creation lowest on record among under-30s
-
9
NK troops disguised as 'indigenous' people in Far East for combat against Ukraine: report
-
10
Opposition leader awaits perjury trial ruling
Komipharm stocks soar upon news of clinical trial application for coronavirus
By Lim Jeong-yeoPublished : Feb. 27, 2020 - 13:32
Komipharm stocks hit the ceiling on Korea’s secondary bourse Kosdaq early Thursday, after the company said it applied for phase 2 and 3 clinical trials of its Panaphix drug for coronavirus as a potential treatment.
The company said it will issue further notice if it gains the Ministry of Food and Drug Safety’s approval for final phase clinical trials targeting 100 coronavirus-confirmed patients.
Investors should be aware that the possibility of any drug winning final commercialization approval from the MFDS is only about 10 percent, Komipharm cautioned.
Yet, the veterinary pharmaceutical company’s stocks closed at 17,550 won ($14.40) on Thursday, up 30 percent from the day before.
Komipharm says Panaphix is a cytokine storm inhibitor that restrains the overproduction of immune cells and their activating compounds, cytokines, whereby it deters virus infection-induced pneumonia.
The company said it seeks to expand the use of Panaphix to cover COVID-19 treatments through the proposed clinical trial.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
The company said it will issue further notice if it gains the Ministry of Food and Drug Safety’s approval for final phase clinical trials targeting 100 coronavirus-confirmed patients.
Investors should be aware that the possibility of any drug winning final commercialization approval from the MFDS is only about 10 percent, Komipharm cautioned.
Yet, the veterinary pharmaceutical company’s stocks closed at 17,550 won ($14.40) on Thursday, up 30 percent from the day before.
Komipharm says Panaphix is a cytokine storm inhibitor that restrains the overproduction of immune cells and their activating compounds, cytokines, whereby it deters virus infection-induced pneumonia.
The company said it seeks to expand the use of Panaphix to cover COVID-19 treatments through the proposed clinical trial.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
